Evidence map›Paper›PMID 27068017›Full record

Trial reportClinical genitourinary cancer2016

Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.

Sujata Narayanan, Anthony Lam, Ulka Vaishampayan, Lauren Harshman, Alice Fan, Russell Pachynski, Shermeen Poushnejad, Denise Haas, Shufeng Li, Sandy Srinivas

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical genitourinary cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Review
  3. Landscape of targeted therapies for advanced urothelial carcinoma.Exploration of targeted anti-tumor therapy · 2024
    Review
  4. Article
  5. Review
  6. Novel Tyrosine Kinase Targets in Urothelial Carcinoma.International journal of molecular sciences · 2021
    Review
  7. Review
  8. Urothelial carcinoma management in elderly or unfit patients.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sujata NarayananStanford Cancer Center, Stanford, CA.
Anthony LamStanford Cancer Center, Stanford, CA.
Ulka VaishampayanKarmanos Cancer Institute, Detroit, MI.
Lauren HarshmanStanford Cancer Center, Stanford, CA.
Alice FanStanford Cancer Center, Stanford, CA.
Russell PachynskiStanford Cancer Center, Stanford, CA.
Shermeen PoushnejadStanford Cancer Center, Stanford, CA.
Denise HaasStanford Cancer Center, Stanford, CA.
Shufeng LiStanford Cancer Center, Stanford, CA.
Sandy SrinivasStanford Cancer Center, Stanford, CA. Electronic address: sandysri@stanford.edu.

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Julie Lynn Boerner · 1985 to 2026
$68.4M
NCI NIH HHS P30 CA022453
6 · The paper itself

Abstract

introductionCurrently, no standard treatments are available for relapsed or refractory urothelial carcinoma (UC). Paclitaxel has demonstrated efficacy in the treatment of UC when used alone or combined with other cytotoxic therapies. We designed a phase II trial combining paclitaxel with pazopanib, a commonly used antiangiogenic agent with significant antitumor activity in various solid tumors. PATIENTS AND

methodsWe enrolled 32 patients with refractory UC who had demonstrated disease progression after 2 previous chemotherapeutic regimens. The patients received paclitaxel 80 mg/m

resultsOf the 28 evaluable patients, a complete response was observed in 3 patients and a partial response in 12, with an ORR of 54% (95% confidence interval, 33.9-72.5). The median progression-free and overall survival was 6.2 and 10 months, respectively. The most frequent side effects noted (all grades) were fatigue (63%), diarrhea (44%), and nausea and vomiting (41%). Hematologic toxicities were common and included (all grades) anemia (69%), neutropenia (38%), and thrombocytopenia (47%). Growth factor support was required for 44% of the patients.

conclusionThe combination of paclitaxel and pazopanib resulted in a promising ORR of 54% in patients with advanced pretreated UC. This represents a greater response rate and median survival than found with other existing second-line regimens for UC and is worthy of further study.

Indexed as

Administration, OralAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellDrug Administration ScheduleFemaleHumansIndazolesMaleMiddle AgedNeoplasm MetastasisPaclitaxelPyrimidinesSulfonamidesIndazolesPaclitaxelpazopanibPyrimidinesSulfonamidesAngiogenesis inhibitorChemotherapyCombinationSecond lineTargeted therapy

Identifiers

PMID27068017
PMCPMC6886228

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.